Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer

Kondalsamy‐Chennakesavan, Srinivas; Yu, Changhong; Kattan, Michael W.; Leung, Yee; Sykes, Peter; Nascimento, Marcelo; Nicklin, James L.; Perrin, Lewis; Crandon, Alex J.; Chetty, Naven; Land, Russell; Garrett, Andrea; Obermair, Andreas

doi:10.1016/j.ygyno.2012.02.022

Cited by 24 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such systems have been based on large databases of historical patients and have incorporated various patient and tumor characteristics and outcomes (11)(12)(13). The Australian nomogram, which is also available as a mobile phone application, has been based on results of 2097 patients and is focused on assessing the individual patient's risk of isolated locoregional and distant recurrence (12). The Memorial Sloan-Kettering Cancer Center nomogram informs on the risk of 3-year OS, without differentiating between local and distant relapse (DR) (11).…”

Section: Discussionmentioning

confidence: 99%

“…For example, the Australian nomogram application is used in clinical practice for discussing individual patients' risks of disease recurrence based on clinical-pathological prognostic factors (12). Likewise, the Mayo Clinic nomogram is used to counsel a patient on the risks and benefits of second staging surgery based on the patient's individual risk of having microscopic pelvic lymph node metastases (13).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials

Creutzberg

Stiphout

Nout

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials

Creutzberg

Stiphout

Nout

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…Multiple retrospective studies have established predictive nomograms for endometrial cancer patients to relevant risk factors for disease relapse and survival [10,11]. A recently published pooled data from the PORTEC-1 and PORTEC-2 trials incorporate these prospective data, which better elucidate outcomes with and without adjuvant therapy and validate these findings with large retrospective datasets [12].…”

Section: Resultsmentioning

confidence: 99%

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Gill

Minkoff

Beriwal

2015

Indian J Gynecol Oncolog

View full text Add to dashboard Cite

Purpose The present article aims to review current management for early-stage endometrioid carcinomas with a specific focus on adjuvant radiotherapy. Methods A comprehensive literature review was conducted regarding management of early-stage endometrioidtype endometrial cancers. Abstracted information included risk of relapse, treatment approach, and morbidity from treatment. Results A majority of low-risk patients are safely managed with observation, with vaginal cuff brachytherapy (VCBT) reserved for those with multiple other risk factors. Intermediate-risk patients are a heterogeneous group with a variable definition; previous trials have established that VCBT alone is suitable for most patients to avoid morbidity of pelvic external beam radiotherapy (EBRT). Highand high-intermediate risk patients warrant pelvic EBRT ± VCBT with or without sequential chemotherapy. Continued controversy exists regarding the optimal VCBT fractionation regimen, with suggestion that higher dose/ fraction regimens may lead to increased vaginal toxicity. Intensity-modulated radiotherapy is being investigated in an effort to reduce late toxicities. Advanced brachytherapy techniques such as image-guided brachytherapy have improved treatment of salvage and medically inoperable patients.Conclusions Identification of risk groups and toxicity reduction through either appropriate radiotherapy techniques or advanced techniques has enabled optimization of adjuvant management for early-stage endometrial cancer.

show abstract

“…In such cases, two possibilities are raised: the pathologist did not mention the presence or absence of LVSI because he did not observe any LVSI or because there was no LVSI. Previous studies evaluating LVSI have shown mixed results concerning the impact of LVSI on reccurence rate [61][62][63][64] . Despite those contradictory results, distinction by LVSI status has recently been suggested to be more relevant than the distinction between stages IA and IB for predicting survival in stage I EC 65 .…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?

Koskas¹,

Rouzier²,

Amant³

2015

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

Endometrial cancer remains the most common malignancy of the female genital tract. Lymph node metastasis is one of the most important prognostic factors and stratification into pelvic lymph node invasion (stage IIIC1) and para-aortic lymph node invasion (stage IIIC2) improved the predictive value of the 2009 FIGO classification.Radiological examination such as magnetic resonance imaging and positron emission tomography-computed tomography do not have good enough sensitivity to avoid lymphadenectomy for the assessment of lymph node invasion. Prediction scores are becoming more and more valuable to exclude lymph node metastasis in low risk groups and biomarkers could help to identify patients with high risk lymph node metastatic probability.The therapeutic role of lymph node dissection remains debated. Several endpoints can be considered to evaluate the opportunity of lymphadenectomy in endometrial cancer.Firstly, we compare survival according to the realization, the extent and the numbers of nodes removed during lymphadenectomy. Secondly, we assess the opportunity of lymphadenectomy in order to tailor adjuvant treatment modalities. Thirdly, we analyze the surgical complication rate after pelvic lymphadenectomy.

show abstract

Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer

Cited by 24 publications

References 25 publications

Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials

Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?

Contact Info

Product

Resources

About